Engflag

SportVis

Quick links to important sections

SportVis

SportVis_FR

Method of action: Analgesic, Anti-Inflammatory, Corrective Metabolism Of Bone And Cartilaginous Tissue, Other Drugs For Disorders Of The Musculo-Skeletal System

Treatment option: Glaucoma, Cataract, Corneal Transplant, Surgery, Cataract Extraction

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of SportVis

Quick Facts

Property Description
Active Ingredient Sodium Hyaluronate (Hyaluronic Acid)
Form Sterile Solution for Injection
Pharmacological Class Orthobiologics (Viscosupplementation Agent)
General Purpose Support and cushioning for injured soft tissues
Origin Biologic (Manufactured by fermentation)

SportVis: Identity, Class, and Composition

SportVis is a specialized viscosupplementation preparation categorized as an Orthobiologic. Its single active component is Sodium Hyaluronate, the sodium salt of Hyaluronic Acid (HA), a key long-chain polysaccharide naturally found in connective tissues. The product is a biologic substance manufactured via fermentation, producing a high-molecular-weight form of HA designed to mimic the structural and viscoelastic properties of natural hyaluronan. This composition is recognized for its high degree of purity and quality, supporting its use in soft tissue therapies.

Formulation, Purpose, and Unique Focus

SportVis is supplied as a sterile, clear solution for injection contained within a pre-filled syringe. The specialized formulation is identified as STABHA (Soft Tissue Adapted Biocompatible Hyaluronic Acid). This unique formulation differentiates the product by its specific focus on treating structures outside the main joint space.

The preparation is administered via peri-articular injection, meaning it is precisely targeted into the soft tissue around the joint, specifically supporting damaged tendons and ligaments, rather than being injected intra-articularly. The general function is to provide mechanical augmentation to these injured non-articular structures. For example, Sodium Hyaluronate treatments provide a supportive effect on tissue repair processes in various soft tissue injuries, facilitating an enhanced local healing environment. The injection helps restore necessary viscoelastic support and lubrication, acting as a cushion to minimize friction and irritation at the injury site. Viscosupplementation agents deliver sustained local support to injured tissues, which contributes to functional stabilization. This targeted approach is central to the product's design, aiming to physically stabilize the affected area while the body's natural processes take effect.

What side effects are possible with SportVis?

Possible Side Effects and Safety Information

The safety profile of SportVis, as an injection containing Sodium Hyaluronate, is defined by adverse reactions and limitations documented in governmental regulatory labeling for the viscosupplementation class of products. The most frequently observed reactions are localized to the area of administration.

Adverse Reactions and Frequency Classification

The incidence of adverse events is primarily characterized by local effects and, rarely, by systemic events. Regulatory documents classify reactions according to their occurrence rate:

Classification Example Adverse Reactions (System-Organ Class)
Common (1% to 10%) Injection site pain, swelling, warmth, and erythema (redness) [General Disorders and Administration Site Conditions]
Rare/Very Rare Anaphylactic or anaphylactoid reactions (severe allergic response), transient hypotension [Immune System Disorders]

Local adverse effects are generally transient and typically resolve spontaneously within a few days following the injection, as noted in regulatory texts.

Key Safety Restrictions and Contraindications

The official labeling includes explicit constraints to ensure safe administration:

  • Hypersensitivity: The product is contraindicated in patients with a known hypersensitivity or allergy to sodium hyaluronate preparations.
  • Local Infection: The product is contraindicated for injection in the presence of existing infections or skin diseases in the area of the injection site.
  • Pediatric and Reproductive Groups: Safety and effectiveness have not been established in pediatric patients or in pregnant or lactating women.

This safety information summarizes the official classification of possible side effects and regulatory constraints, focusing on the most common local events and the very rare potential for serious systemic reactions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for injectable Sodium Hyaluronate (SportVis) primarily addresses the risk of over-administration at the injection site, rather than classic systemic overdose. As a locally administered orthobiologic, systemic toxicity is not expected or generally documented in regulatory prescribing information.

Documented Manifestations and Actions

Feature Regulatory Statement Summary
Manifestations Over-administration may result in localized symptoms, including increased pain, swelling or effusion, and redness (erythema) at the soft tissue injection site.
Antidote No specific pharmacological antidote is known (or documented) in the official prescribing information for this substance.
Supportive Measures Management is described as symptomatic and supportive. This may involve resting the affected area and applying local cooling to mitigate swelling and pain.

When to Seek Urgent Medical Help

Immediate medical attention is officially required for specific conditions. Patients must seek immediate medical attention for any severe, persistent, or unexpected adverse local events. Urgent help is also mandated if there are any signs suggestive of a systemic allergic reaction, such as difficulty breathing or widespread rash, even though these are considered rare events in regulatory documents. Hospital monitoring may be required in circumstances involving severe local reactions.

Therapeutic Uses of SportVis

Quick Facts

  • Lateral Epicondylitis: Used to assist in the management of chronic pain associated with tennis elbow.
  • Acute Ankle Sprains: Used to support recovery and may help to reduce discomfort following a recent ankle sprain.
  • Tendon and Ligament Injuries: An option to support recovery and promote functional measures in various soft tissue injuries.

SportVis is a treatment option used to support recovery in specific soft tissue injuries involving tendons and ligaments. It is administered to assist in the management of pain and promote improved function in the affected area.

This treatment is used in patients who have lateral epicondylitis (commonly known as tennis elbow) and may also be used following acute ankle sprains to support the body's healing mechanism. The application is intended to contribute to symptomatic relief in the localized area.

Clinical observations suggest that the use of hyaluronic acid injections may be associated with improved pain parameters and functional scores for certain soft tissue conditions.

Patients should consult with a healthcare professional to determine if this treatment is appropriate for their specific condition and to understand its proper use.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use SportVis — Official Regulatory Information

The eligibility profile for SportVis (Sodium Hyaluronate injections) is defined by mandatory regulatory exclusions and population constraints established by health authorities. Use is primarily established for the Adult Population.

Eligibility Classification Official Regulatory Statement
Absolute Contraindication The medicine is contraindicated in patients with a known hypersensitivity to the preparation (sodium hyaluronate or protein components) and in patients with infections or skin diseases at the planned injection site. Use is also prohibited for patients with known systemic bleeding disorders.
Use Not Established Safety and effectiveness have not been established in the pediatric population (leq 21 years of age).
Physiological State Use in pregnant and lactating women is not established, as safety data for these groups is insufficient.
Geriatric Patients No specific information is available in official labeling regarding the relationship of age to the effects in this population.

The official labeling defines who can and cannot use the medicine by establishing clear contraindications that strictly prohibit use for specific high-risk groups, such as those with localized infections or allergies to the active substance. Furthermore, regulatory documents explicitly state that safety and effectiveness have not been established for children, pregnant women, and breastfeeding women.

What should I know about interactions with other medicines?

The official regulatory documentation for Sodium Hyaluronate injections outlines interaction patterns that are strictly limited to the site and procedure of administration. This specific focus exists because no systemic drug–drug interactions, such as those involving cytochrome P450 enzymes or drug transporters, are documented in official regulatory prescribing information.

Chemical Incompatibility

The profile is governed by a mandatory procedural restriction: it is explicitly prohibited to use disinfectants containing Quaternary Ammonium Salts, including agents like Benzalkonium Chloride, for skin preparation prior to the injection. This is due to a chemical incompatibility where these substances are documented to cause the active ingredient, Sodium Hyaluronate, to precipitate.

Local Co-Administration

In addition to this chemical constraint, the regulatory labels note a restriction regarding other local treatments. The safety and effectiveness of the product’s concurrent administration with other injectable products (such as local anesthetics or corticosteroids) into the same local area have not been formally established. No documented systemic interaction exists with oral medications, food, alcohol, supplements, or herbal products.

Mechanism of Action

The mechanism of action for Sodium Hyaluronate involves a dual physical and biochemical modulation of the peri-articular soft tissue.

Viscoelastic Augmentation and Frictional Control

The immediate mechanism involves the physical augmentation of the soft tissue environment. The high-molecular-weight preparation restores the viscoelastic properties of the extracellular matrix, acting as a mechanical cushion and lubricant. This physical action helps reduce friction and shear stress between moving structures, directly minimizing movement-induced mechanical stress and providing localized mechanical reinforcement to the altered tissue architecture.

Local Anti-Inflammatory Signaling

The biochemical domain acts to downregulate pro-inflammatory signals by binding to receptors (e.g., CD44 on tenocytes) and scavenging Reactive Oxygen Species (ROS). This targeted action inhibits the production of inflammatory mediators (like PGE2 and MMPs), leading to the reduction of local inflammatory mediator activity and direct modulation of peripheral nociceptor signaling.

Support for Extracellular Matrix Remodeling

The sustained physiological effect is driven by the influence on cellular activity. The mechanism modulates tenocyte viability and proliferation, encouraging the organized synthesis of Type I collagen. This action helps to restore the structural organization of the soft tissue architecture, supporting the long-term tenocyte-mediated matrix reorganization.

Dosage and Administration Information

How to Use SportVis: Official Administration Guidelines

SportVis is provided as a sterile solution in a single-use pre-filled syringe containing 12 mg/1.2 mL of sodium hyaluronate. Its administration is restricted to a healthcare professional trained in peri-articular injection techniques, and it is not suitable for self-administration.

Administration Details

Attribute Administration Standards
Route of Administration Peri-articular injection (into the soft tissue surrounding the damaged tendons/ligaments). Injection into the tendon, blood vessel, or hematoma must be avoided.
Dosage and Course A fixed course of two injections. Each dose is 1.2 mL.
Dosing Schedule For Acute Ankle Sprains: The first injection is given, preferably within 48 hours of injury, followed by the second injection 2–3 days later. For Lateral Epicondylalgia: The first injection is given, followed by the second injection 1 week later.

Procedural Requirements

Administration requires specific steps to maintain sterility and accuracy:

  • Preparation: The injection site must be disinfected, and a separate, sterile needle (e.g., 27-gauge) must be used.
  • Technique: The healthcare professional must apply a precise, site-specific fanning technique to administer the solution in multiple planes as the needle is withdrawn from the peri-articular space. This technique varies depending on the site (ankle or elbow).
  • Children and Pregnancy: Safety and effectiveness have not been established in children under 18 years of age or in patients who are pregnant or nursing.

The full usage protocol is defined by this mandatory two-dose schedule and the requirement for professional, anatomically precise injection.

Recent Clinical Evidence

SportVis: Recent Clinical Evidence

SportVis is a formulation of hyaluronic acid (HA) developed for injection near damaged soft tissues, such as tendons and ligaments. The specific HA preparation is sometimes referred to as Soft Tissue Adapted Biocompatible Hyaluronic Acid (STABHA™).

Research has explored the use of hyaluronic acid injections for various musculoskeletal conditions, including soft tissue injuries where the HA is applied peri-articularly (around the joint) rather than intra-articularly (inside the joint).

Key Areas of Investigation

Clinical studies have primarily focused on two distinct injury types where SportVis is indicated:

  • Chronic Lateral Epicondylitis (Tennis Elbow): Studies have investigated the effects of the injection on pain and functional outcomes in patients with persistent elbow pain. One randomized controlled trial found that patients receiving the HA treatment reported improvements in pain at rest and after grip testing when compared to placebo, with these effects persisting at one-year follow-up.
  • Acute Ankle Sprains: Research has also evaluated the role of the injection in managing acute ankle sprains, typically Grade 1 or 2. Study endpoints included measures of pain and the restoration of function in the affected ligaments.

Evidence and Comparative Findings

While evidence for hyaluronic acid in tendon and ligament injuries is still developing, some studies have evaluated its performance against other common treatments:

Comparison Findings Summary
VS. Corticosteroids Some research suggests HA may offer comparable pain relief to corticosteroids in the short term, with potentially better functional outcomes in the long term, particularly in tendinopathies.
VS. Physiotherapy/Rehabilitation Some trials have indicated that HA injections combined with an exercise protocol may lead to an earlier return to pre-injury activity compared to exercise alone.

Overall, the available evidence suggests that this form of hyaluronic acid is generally well-tolerated. However, regulatory bodies emphasize that the findings from small trials should be interpreted with caution, and its use is subject to the specific indications approved by local health authorities.

How should SportVis be stored and disposed of?

How to Store and Dispose of SportVis™

Official regulatory information dictates specific conditions for storing and handling SportVis to maintain product integrity.

Storage Requirements

SportVis must be stored at a temperature between 5 C and 25 C (or 41 F to 77 F). It is a mandatory requirement that the product must not be frozen at any time. The pre-filled syringe should be kept in its original package and must be protected from light until the moment of use. The packaging should be inspected before use; do not administer the injection if the sterile package is damaged.

Handling and Disposal

The product must not be used after the expiration date printed on the label. SportVis is supplied for single use only. Any remaining solution in the syringe after injection, or any unused, expired product, must be discarded immediately. Disposal must be carried out in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

flagMexico

Equivalent of SportVis found in:

A-Z Index: